Tenecteplase (TNK) in the Treatment of Intracerebral Hemorrhage (ICH)

Summary

The overall purpose of this study is to look at the safety and effectiveness of administering Tenecteplase (TNK) into the brain bleed (hematoma) instead of another clot-dissolving drug known as recombinant tissue plasminogen activator (rtPA), which is the current standard practice. Clot dissolving (Fibrinolytic) drugs work to break down blood clots and have been found to improve health outcomes when applied directly into the hematoma within the brain. Patients who take part in this study will undergo the same surgical procedure that would normally be performed to treat them, but with the exception of TNK not rtPA.

Timeline

Start

2026-09-15

Primary completion

2028-01-15

Completion

2028-12-31

Drugs

Indications